首页> 外国专利> METHOD OF PREDICTING WHETHER A KIDNEY TRANSPLANT RECIPIENT IS AT RISK OF HAVING ALLOGRAFT LOSS

METHOD OF PREDICTING WHETHER A KIDNEY TRANSPLANT RECIPIENT IS AT RISK OF HAVING ALLOGRAFT LOSS

机译:预测肾脏移植受体是否有异体移植风险的方法

摘要

Organ transplantation is currently recognised as the treatment of choice for patients with end-stage renal disease (ESRD), which is an underestimated but increasing burden worldwide. Despite the pressing need for improving patients risk stratification raised by transplant societies as well as regulatory agencies, no risk-stratification system exists that adequately predicts transplant patients' individual risk of allograft loss. This currently represents a limitation for improving patient management, as well as for defining early surrogate end points for clinical trials and development of pharmaceutical agents. The inventors now report the development and validation of an integrative risk prediction score to predict kidney allograft survival of individual patients (NCT03474003). The iBox risk prediction score is the first integrative system validated in several independent populations from Europe & North America as well as across 3 clinical trials (NCT01079143, EudraCT2007-003213-13, NCT01873157) covering distinct clinical scenarios. In particular, the advantages brought by the iBox risk prediction score are i) improved discrimination performance by combining traditional prognostic factors with mechanistically informed parameters, ii) outperformance when compared with currently existing scoring systems, iii) generalisability when assessed in geographically distinct cohorts from Europe and North America, iv) transportability at different times of evaluation post-transplant, v) performance in a variety of clinical scenarios including clinical trials and vi) readily accessible to clinicians and patients by an online tool for patient risk calculation. Thus, the present invention relates to a method of predicting whether a kidney transplant recipient is at risk of having allograft loss by implementing the iBox risk prediction score.
机译:目前公认器官移植是终末期肾病(ESRD)患者的首选治疗方法,该疾病在世界范围内被低估,但负担日益增加。尽管迫切需要改善移植协会和监管机构提出的患者风险分层,但尚无可充分预测移植患者个体同种异体移植风险的风险分层系统。当前,这代表了改善患者管理以及为临床试验和开发药物定义早期替代终点的局限性。现在,发明人报告了用于预测个体患者的肾脏同种异体移植存活的综合风险预测评分的开发和验证(NCT03474003)。 iBox风险预测评分是第一个在欧洲和北美的数个独立人群中以及在涵盖不同临床场景的3项临床试验(NCT01079143,EudraCT2007-003213-13,NCT01873157)中得到验证的集成系统。特别是,iBox风险预测得分带来的优势是:i)通过将传统的预后因素与机械学问的参数相结合,提高了歧视表现; ii)与当前现有的评分系统相比表现出色; iii)在来自欧洲不同地区的人群中进行了普遍性评估iv)移植后评估的不同时间的可运输性,v)在包括临床试验在内的各种临床情况下的表现,以及vi)临床医生和患者可通过在线风险计算工具轻松获得。因此,本发明涉及通过实现iBox风险预测分数来预测肾移植接受者是否具有同种异体移植风险的方法。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号